• letlifehappen's Avatar

    letlifehappen posted a blog post

    Written by clinical psychologist Michael J. Canzoniero PhD, “In Strictest Confidence” is a novel that dramatizes the damage of childhood abuse and neglect. Characters are developed who embody the repercussions of their mistreatment. Their histories – based on real events – elucidate the horrors of child abuse. For balance, the difficult childhoods of both the protagonist and the antagonists are ...
    The post “In Strictest Confidence.” – new book addressing child abuse, mental health appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    Source: Aileron Therapeutics, Inc. From: clinicalleader.com Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced that it has entered into a clinical trial collaboration with Pfizer to evaluate the combination of Aileron’s ALRN-6924 and Pfizer’s palbociclib, also known as IBRANCE®, in MDM2-amplified cancers. Overexpression of MDM2 in ...
    The post Aileron Enters Clinical Trial Collaboration With Pfizer To Evaluate ALRN-6924 In Combination With IBRANCE® (Palbociclib) In MDM2-Amplified Cancers appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    From: fda.gov The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker). This is the second time the agency has approved a cancer treatment based on a common biomarker across different types of tumors rather than the location in the body where ...
    The post FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    From: eurekalert.org Scientists have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the immune system. It is the first time that cancer-associated fibroblasts within solid tumours – healthy cells that are tricked into protecting the cancer from the immune system and ...
    The post New dual-action cancer-killing virus appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    From: prweb.com uBiome, the leader in microbial genomics, today announced the first stage of companion diagnostic development with Puma Biotechnology, Inc. (NASDAQ: PBYI) to investigate the role of the microbiome in adverse events related to neratinib treatment of patients with HER2-positive breast cancer. “This companion diagnostic and clinical trial work is an important part of the future of uBiome,” said ...
    The post uBiome Announces First Stage of Companion Diagnostic Development in Collaboration with Puma Biotechnology, Inc. appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    By: Angelica Welch From: oncnursingnews.com The optimal duration of treatment for patients with HER2-positive breast cancer has been called into question by recent findings from the NSABP B-52, PERSEPHONE, and APT clinical trials. Priya Rastogi, MD, senior associate medical director, NSABP Medical Affairs, associate professor of Medicine, University of Pittsburgh, shed light on the subject during a presentation she gave ...
    The post Trials Answer Questions About Duration of Treatment in HER2+ Breast Cancer appeared first on Let Life Happen.